Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed relapsed B-cell non-Hodgkin's lymphoma (NHL)~  * Diffuse large cell B-cell lymphoma~ * Grade III follicular center-cell lymphoma~ * Primary mediastinal B-cell lymphoma~* CD20 positive~* First relapse after doxorubicin containing regimen~* Documented remission of at least 3 months after first-line chemotherapy~* No Epstein-Barr virus post-transplantation lymphoproliferative disorder~* No CNS involvement~PATIENT CHARACTERISTICS:~Age:~* 18 to 65~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* No hepatic dysfunction~* Bilirubin less than 2.5 times upper limit of normal (ULN)~* Transaminases less than 2.5 times ULN~Renal:~* No renal dysfunction~* Creatinine less than 2.0 mg/dL OR~* Creatinine clearance greater than 40 mL/min~Cardiovascular:~* No severe cardiac dysfunction~* No New York Heart association class II-IV heart disease~Pulmonary:~* No severe pulmonary dysfunction~* Vital capacity or diffusion capacity at least 70% predicted unless related to NHL involvement~Other:~* No active uncontrolled infection~* HIV negative~* No intolerance to exogenous protein administration~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 1 month since prior immunotherapy~Chemotherapy:~* See Disease Characteristics~* At least 1 month since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 1 month since prior radiotherapy~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).